Paraskevi Giannakakou

Affiliations: 
Weill Cornell Medical College, New York, NY, United States 
Area:
Oncology, Cell Biology, Pharmacology
Google:
"Paraskevi Giannakakou"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Jing H, Hu J, He B, et al. (2016) A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. Cancer Cell. 29: 767-768
Jing H, Hu J, He B, et al. (2016) A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. Cancer Cell. 29: 607
Jing H, Hu J, He B, et al. (2016) A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. Cancer Cell. 29: 297-310
Diamond E, Molina AM, Carbonaro M, et al. (2015) Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy. Critical Reviews in Oncology/Hematology
Thadani-Mulero M, Portella L, Sun S, et al. (2014) Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Research. 74: 2270-82
Thadani-Mulero M, Nanus DM, Giannakakou P. (2012) Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Research. 72: 4611-5
Carbonaro M, Escuin D, O'Brate A, et al. (2012) Microtubules regulate hypoxia-inducible factor-1α protein trafficking and activity: implications for taxane therapy. The Journal of Biological Chemistry. 287: 11859-69
Darshan MS, Loftus MS, Thadani-Mulero M, et al. (2011) Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Research. 71: 6019-29
Kanakkanthara A, Wilmes A, O'Brate A, et al. (2011) Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes. Molecular Cancer Therapeutics. 10: 1419-29
Kauh J, Chanel-Vos C, Escuin D, et al. (2011) Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies. Cancer. 117: 4049-59
See more...